标题
Targeting Trop-2 in cancer: Recent research progress and clinical application
作者
关键词
-
出版物
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1878, Issue 4, Pages 188902
出版商
Elsevier BV
发表日期
2023-04-29
DOI
10.1016/j.bbcan.2023.188902
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Bystander effect of antibody–drug conjugates: fact or fiction?
- (2022) Federica Giugliano et al. Current Oncology Reports
- TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.
- (2022) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)
- (2022) H.S. Rugo et al. ANNALS OF ONCOLOGY
- Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
- (2022) Sibylle Loibl et al. EUROPEAN JOURNAL OF CANCER
- Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2022) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- MA13.07 TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
- (2022) B. Levy et al. Journal of Thoracic Oncology
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models
- (2021) Tomohiro Tanaka et al. ONCOLOGY REPORTS
- Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer
- (2021) Weiyu Chen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Datopotamab deruxtecan (Dato-DXd), a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells
- (2021) Daisuke Okajima et al. MOLECULAR CANCER THERAPEUTICS
- Stepping forward in antibody-drug conjugate development
- (2021) Yiming Jin et al. PHARMACOLOGY & THERAPEUTICS
- Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads
- (2021) Danielle M. Lussier et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Simultaneous engagement of tumor and stroma targeting antibodies by engineered NK-92 cells expressing CD64 controls prostate cancer growth
- (2021) Hallie M Hintz et al. Cancer Immunology Research
- Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer
- (2021) Emanuela Guerra et al. NEOPLASIA
- The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer
- (2021) Domenico Ribatti et al. Cancers
- Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
- (2021) Paolo Tarantino et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma
- (2021) Ramona Erber et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3
- (2021) Young Min Chung et al. Journal for ImmunoTherapy of Cancer
- Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2
- (2021) Meng Sun et al. iScience
- Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
- (2020) En-Chi Hsu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TP63 isoform expression is linked with distinct clinical outcomes in cancer
- (2020) Armand Bankhead et al. EBioMedicine
- Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
- (2020) Emanuele Perrone et al. Frontiers in Oncology
- SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.
- (2020) Yongheng Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Trop2 inhibition of P16 expression and the cell cycle promotes intracellular calcium release in OSCC
- (2020) Lizhou Jia et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Antibody–Drug Conjugates for Cancer Therapy
- (2020) Umbreen Hafeez et al. MOLECULES
- Could trop-2 overexpression indicate tumor aggressiveness among prostatic adenocarcinomas?
- (2020) İlker Akarken et al. Annals of Diagnostic Pathology
- The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer
- (2019) Wei Zhao et al. Cancer Medicine
- Targeting Trop-2 in solid tumors: future prospects
- (2019) Saif Zaman et al. OncoTargets and Therapy
- A novel human monoclonal Trop2-IgG antibody inhibits ovarian cancer growth in vitro and in vivo
- (2019) Jinrong Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C α/δ (PKCα/δ) enhances cell motility
- (2019) Yugo Mori et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Induction of Trop-2 expression through the binding of galectin-3 to MUC1
- (2019) Tomoko Yamashita et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Photoimmunotherapy targeting biliary‐pancreatic cancer with humanized anti‐TROP2 antibody
- (2019) Takashi Nishimura et al. Cancer Medicine
- Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody–Drug Conjugate (Sacituzumab Govitecan)
- (2019) Renu Pandey et al. ANALYTICAL CHEMISTRY
- In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma
- (2019) Chanhee Han et al. GYNECOLOGIC ONCOLOGY
- Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
- (2019) Emanuele Perrone et al. Molecular Oncology
- TROP2 methylation and expression in tamoxifen-resistant breast cancer
- (2018) Stephanie M. Zimmers et al. Cancer Cell International
- Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition
- (2018) Ján Remšík et al. CARCINOGENESIS
- The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma
- (2018) Xueyang Yang et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
- (2018) Gentry T. King et al. INVESTIGATIONAL NEW DRUGS
- Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates
- (2018) Eshita Khera et al. BIODRUGS
- Prostate cancer sheds the αvβ3 integrin in vivo through exosomes
- (2018) Shiv Ram Krishn et al. MATRIX BIOLOGY
- Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
- (2018) Maria Quanz et al. Oncotarget
- TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling
- (2018) Sarah T.K. Sin et al. GYNECOLOGIC ONCOLOGY
- Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer
- (2017) Paul Malik et al. PHARMACEUTICAL RESEARCH
- Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
- (2016) M. Martin et al. ANNALS OF ONCOLOGY
- Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
- (2016) Hans-Peter Gerber et al. BIOCHEMICAL PHARMACOLOGY
- Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors
- (2016) Emanuela Guerra et al. CLINICAL CANCER RESEARCH
- Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
- (2016) C.-H. Chang et al. MOLECULAR CANCER THERAPEUTICS
- RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
- (2016) P. Strop et al. MOLECULAR CANCER THERAPEUTICS
- Altering Antibody–Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability
- (2016) Kevin J. Hamblett et al. MOLECULAR PHARMACEUTICS
- TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma
- (2016) Andrey Bychkov et al. PATHOLOGY
- Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
- (2016) Jose F. Ponte et al. NEOPLASIA
- Pr1E11, a novel anti-TROP-2 antibody isolated by adenovirus-based antibody screening, recognizes a unique epitope
- (2015) Masahiro Ikeda et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates
- (2015) Magdalena Dorywalska et al. BIOCONJUGATE CHEMISTRY
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
- (2015) Shin Kan et al. BMC CANCER
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
- (2015) R. M. Sharkey et al. CLINICAL CANCER RESEARCH
- TROP-2 expression in papillary thyroid carcinoma
- (2015) Anthony Simms et al. DIAGNOSTIC CYTOPATHOLOGY
- A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells
- (2015) YUKARI NISHII et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates
- (2015) Shi Xu PHARMACEUTICAL RESEARCH
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts
- (2015) Marco Trerotola et al. Oncotarget
- Development of a sensitive screening method for selecting monoclonal antibodies to be internalized by cells
- (2014) Miki Yamaguchi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer
- (2014) S. Lutje et al. CANCER RESEARCH
- TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study
- (2014) T. Addati et al. CYTOPATHOLOGY
- Targeting CD8+ T-cell tolerance for cancer immunotherapy
- (2014) Stephanie R Jackson et al. Immunotherapy
- Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications
- (2014) Andreas Maderna et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer
- (2014) Donglin Liu et al. Molecular Cancer
- Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2-Bispecific Antibody Is Enhanced in Combination with Interferon-
- (2014) E. A. Rossi et al. MOLECULAR CANCER THERAPEUTICS
- Trop-2 Is a Determinant of Breast Cancer Survival
- (2014) Federico Ambrogi et al. PLoS One
- Trop-2 Promotes Prostate Cancer Metastasis By Modulating 1 Integrin Functions
- (2013) M. Trerotola et al. CANCER RESEARCH
- Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
- (2013) Pavel Strop et al. CHEMISTRY & BIOLOGY
- Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody
- (2013) Catharina M. van Rij et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain
- (2013) Tilen Vidmar et al. PROTEIN EXPRESSION AND PURIFICATION
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma
- (2012) Jau-Chen Lin et al. EMBO Molecular Medicine
- Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis
- (2012) Marco Trerotola et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2-Expressing Epithelial Cancers
- (2012) R. M. Sharkey et al. JOURNAL OF NUCLEAR MEDICINE
- Upregulation of Trop-2 quantitatively stimulates human cancer growth
- (2012) M Trerotola et al. ONCOGENE
- The Trop-2 signalling network in cancer growth
- (2012) E Guerra et al. ONCOGENE
- Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody
- (2011) Joyce Varughese et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
- (2011) T. M. Cardillo et al. CLINICAL CANCER RESEARCH
- Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma
- (2011) Eliana Bignotti et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
- (2011) Rhoda Raji et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models
- (2011) R. M. Sharkey et al. MOLECULAR CANCER THERAPEUTICS
- Bevacizumab improves the delivery and efficacy of paclitaxel
- (2010) Mieko Yanagisawa et al. ANTI-CANCER DRUGS
- Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients
- (2010) Eliana Bignotti et al. EUROPEAN JOURNAL OF CANCER
- Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
- (2010) Rafael Cubas et al. Molecular Cancer
- Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells
- (2010) Chien-Hsing Chang et al. MOLECULAR CANCER THERAPEUTICS
- Antiinflammatory Effects of the ETS Factor ERG in Endothelial Cells Are Mediated Through Transcriptional Repression of the Interleukin-8 Gene
- (2009) Lei Yuan et al. CIRCULATION RESEARCH
- A Bicistronic CYCLIN D1-TROP2 mRNA Chimera Demonstrates a Novel Oncogenic Mechanism in Human Cancer
- (2008) E. Guerra et al. CANCER RESEARCH
- Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers
- (2008) J. Wang et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now